Metformin inhibits 17β-estradiol-induced epithelial-to-mesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKα signaling in endometrial adenocarcinoma cells.
Metformin inhibits 17β-estradiol-induced epithelial-to-mesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKα signaling in endometrial adenocarcinoma cells.
复制标题
DOI：
10.18632/oncotarget.7040
复制
发表时间：
2016-04-19
期刊：
影响因子：
--
通讯作者：
Zhang H
中科院分区：
文献类型：
--
作者：
Liu Z;Qi S;Zhao X;Li M;Ding S;Lu J;Zhang H
The potential role of metformin in treating endometrial cancer remains to be explored. The current study investigated the role of metformin in 17β-estradiol-induced epithelial-mesenchymal transition (EMT) in endometrial adenocarcinoma cells. We found that 17β-estradiol promoted proliferation and migration, attenuated apoptosis in both estrogen receptor (ER) positive and ER negative endometrial adenocarcinoma cells (Ishikawa and KLE cells, respectively). Metformin abolished 17β-estradiol-induced cell proliferation and reversed 17β-estradiol-induced EMT in Ishikawa cells. In addition, metformin increased the expression of βKlotho, a fibroblast growth factors (FGFs) coreceptor, and decreased ERK1/2 phosphorylation in both Ishikawa and KLE cells. Decreased expression of βKlotho was noted in human endometrial adenocarcinomas, and plasmid-driven expression of βKlotho in Ishikawa cells abolished 17β-estradiol-induced EMT via inhibiting ERK1/2 signaling. βKlotho expression and metformin show synergetic effects on the proliferation and the EMT in Ishikawa cells. Furthermore, we demonstrated that the anti-EMT effects of metformin could be partly abolished by introducing Compound C, a specific AMPKα signaling inhibitor. In conclusion, metformin abolishes 17β-estradiol-induced cell proliferation and EMT in endometrial adenocarcinoma cells by upregulating βKlotho expression, inhibiting ERK1/2 signaling, and activating AMPKα signaling. Our study provides novel mechanistic insight into the anti-tumor effects of metformin.
登录
查看更多内容
影响因子：
11.5
作者：
Mell, LK;Meyer, JJ;Mundt, AJ
通讯作者：
Mundt, AJ
影响因子：
8.2
作者：
Friberg, E.;Orsini, N.;Wolk, A.
通讯作者：
Wolk, A.
影响因子：
7.3
作者：
Chen, Yi-Jen;Li, Hsin-Yang;Yang, Muh-Hwa
通讯作者：
Yang, Muh-Hwa
二甲双胍通过抑制 IL-6 信号传导和 EMT 逆转，在体外和体内使 EGFR-TKI 耐药的人肺癌细胞变得敏感
影响因子：
11.5
作者：
Li, Li;Han, Rui;He, Yong
通讯作者：
He, Yong
影响因子：
4.7
作者：
Ding, Jing-Xin;Feng, You-Ji;Yin, Lian-Hua
通讯作者：
Yin, Lian-Hua